Allergy Therapeutics (AGY)


Latest News

Allergy Therapeutics co-development agreement with Ergomed

Allergy Therapeutics has entered into a co-development collaboration agreement with Ergomed for the clinical developme...

Co-development agreement with Ergomed plc

RNS Number: 0248Z Allergy Therapeutics PLC 12 December 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics enters co-development agreement with Ergomed plc 12 December 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces it h...

Holding(s) in Company

RNS Number: 7505Y Allergy Therapeutics PLC 07 December 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Allergy ...

All resolutions passed at AGM of Allergy Therapeutics

Allergy Therapeutics has announced that all resolutions were passed by shareholders at today's Annual General Meeting. A...

All News

12-12-17Allergy Therapeutics co-development agreement with Ergomed StockMarketWire
12-12-17Co-development agreement with Ergomed plcRNS
07-12-17Holding(s) in CompanyRNS
22-11-17All resolutions passed at AGM of Allergy TherapeuticsStockMarketWire
22-11-17Result of AGMRNS
21-11-17Block Listing ApplicationRNS
13-11-17Allergy Therapeutics to Present at Jefferies 2017RNS
07-11-17Director/PDMR ShareholdingRNS
07-11-17Director/PDMR ShareholdingRNS
19-10-17Publication of Annual Report and notice of AGMRNS
19-10-17Allergy Therapeutics starts dosing for grass pollen trial StockMarketWire
19-10-17Commencement of dosing in PQ Grass Phase II TrialRNS
12-10-17Holding(s) in CompanyRNS
12-10-17Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
12-10-17Director/PDMR ShareholdingRNS
10-10-17Allergy Therapeutics 'continuing to gain market share'StockMarketWire
10-10-17Hardman Research: Continuing to gain market shareRNS
28-09-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
28-09-17Allergy Therapeutics pre-tax losses narrow StockMarketWire
28-09-17Preliminary ResultsRNS
18-09-17Allergy Therapeutics gets approval for PQ Grass trial StockMarketWire
18-09-17Approval for PQ Grass Phase II trialRNS
11-09-17Allergy Therapeutics expands R&D and clinical team StockMarketWire
11-09-17Expansion of Clinical Development and R&D teamsRNS
15-08-17 Allergy Therapeutics schedules FY results StockMarketWire
15-08-17Notice of ResultsRNS
18-07-17Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLCStockMarketWire
18-07-17Allergy Therapeutics ahead of forecasts StockMarketWire
18-07-17Trading UpdateRNS
06-07-17Publication of adjuvant studies in journalsRNS
27-06-17Investor and analyst site visitsRNS
19-06-17Allergy Therapeutics hosts satellite symposium at EAACIStockMarketWire
19-06-17Satellite Symposium at EAACI 2017RNS
06-06-17Directorate changesRNS
02-06-17Holding(s) in CompanyRNS
13-04-17Issue of EquityRNS
05-04-17Hardman Research: Development across portfolioRNS
04-04-17Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLCStockMarketWire
29-03-17Interim Results for six months ended 31 Dec 2016RNS
16-03-17Allergy Therapeutics recruits first patient in birch pollen trial StockMarketWire

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account